GlassScriptPhysician profile
Nader H Chadda
NPI 1225215064
$94,608.79
in general payments reported to CMS, 2019-2025
37 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $238 · 2021: $1,771 · 2022: $20K · 2023: $18K · 2024: $31K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $69K · Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $68,500.02 |
| Food and Beverage | $3,647.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $89,725.85 | 2021-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Janssen Pharmaceuticals, INC | $468.96 | 2019-2024 | Xarelto |
| Medtronic, INC. | $417.42 | 2021-2025 | Linq II, Micra, Abre |
| Amgen INC. | $407.30 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $359.96 | 2020-2025 | Watchman Flx, Varithena Administration Pack, Eluvia |
| Inari Medical, INC. | $283.70 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.32 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $255.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.84 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $210.28 | 2021-2025 | Verquvo |
| Endologix LLC | $186.11 | 2022 | |
| Abbott Laboratories | $163.47 | 2020-2021 | |
| Thrombolex, INC. | $155.44 | 2025 | Bashir Endovascular Catheter |
| Astrazeneca Pharmaceuticals LP | $147.37 | 2019-2025 | Farxiga |
| Philips North America LLC | $132.68 | 2022-2024 | (Dd3) Venous Stent Und, (Br7) Peripheral Specialty Balloon, (Br6) Re Entry |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $132.68 | 2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $128.49 | 2021-2025 | |
| Reflow Medical INC | $116.06 | 2025 | |
| Esperion Therapeutics, INC. | $109.96 | 2023-2024 | Nexletol, Nexlizet |
| Lexicon Pharmaceuticals, INC. | $103.08 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $88.72 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $77.23 | 2025 | Venclose Maven Catheter |
| Stryker Corporation | $54.25 | 2025 | Clottriever Bold Catheter, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Scpharmaceuticals INC. | $47.63 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.07 | 2025 | |
| Cvrx, INC. | $40.45 | 2023-2024 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $40.31 | 2023 | Optimizer |
| Tactile Systems Technology INC | $36.09 | 2025 | Flexitouch Plus, Nimbl |
| Sanofi-Aventis U.S. LLC | $33.74 | 2023 | |
| Amarin Pharma, INC. | $30.65 | 2019-2021 | |
| Shockwave Medical, INC | $27.61 | 2025 | |
| Novo Nordisk INC | $22.57 | 2024 | Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $22.05 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $21.92 | 2024 | Camzyos |
| W. L. Gore & Associates, INC. | $12.98 | 2023 | Gore Viabahn Vbx Balloon Expandable Endo |
| Cook Medical LLC | $10.91 | 2019 | |
| Cardiovascular Systems INC. | $5.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Chadda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.